SV Health Investors Nachrichten und Aktivitäten

SV Health Investors hat eine direkte Präsenz in 2 Ländern.

Siehe das Organigramm mit seine 39 wichtigsten Führungskräfte

Die meist gesuchten Biographien bei SV Health Investors

• Eugene Hill, Chairman of the Board
• Brent Faduski, Chief Financial Officer, Chief Compliance Officer a...
• Greg Madden, Managing Partner, Medical Devices and Healthcare

Letzte Veränderungen der Führungskräfte auf SV Health Investors

• A.J. Rossi der/die zuvor Principal, Healthcare Growth-Buyout war, wurde zum Partner, Healthcare Growth-Buyout befördert  (Nachrichten veröffentlicht am 23, Dezember 2024).

Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von SV Health Investors nachzuverfolgen.

SV Health Investors hat 1.573 Konkurrenten , einschließlich BlackRock (USA), KKR (USA) und Vanguard (USA).

Popular M&A news in Fond

• Seven2 has announced the acquisition of HRK Lunis  (veröffentlicht am 3, April 2025).
• Fluent hat RIV Capital erworben (veröffentlicht am 20, Dezember 2024).
• RIV Capital and Fluent have announced they will merge  (veröffentlicht am 14, Oktober 2024)..

Andere vorgeschlagene Kontakte der Fond branche

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer bei Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director bei Vanguard
• Hemant Taneja - Chief Executive Officer and Managing Director bei General Catalyst Partners

Mehr über die Fond branche erfahren

Neueste Pressemitteilungen nach SV Health Investors

• Therini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases - SV Health Investors
• AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN - SV Health Investors
• Centauri Health Solutions Acquires MedAllies, Broadens Health Data Network to Support Mission Critical Use Cases - SV Health Investors
• Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - SV Health Investors
• Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets - SV Health Investors
• Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - SV Health Investors
• News - SV Health Investors
• Endlyz Therapeutics launches and unveils its portfolio of programmes targeting Parkinson’s disease - SV Health Investors
• British Patient Capital announces £25m commitment to SV Health Investors’ Dementia Discovery Fund 2 - SV Health Investors
• Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 - SV Health Investors
• View more press releases Close

Social media about SV Health Investors

• SV Health Investors auf Wikipedia, Google News & Yahoo Finance
• SV Health Investors auf LinkedIn, Twitter & YouTube